Mhg. Rep et al., Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients, J NEUROIMM, 96(1), 1999, pp. 92-100
Interferon (IFN)-beta has been shown to favorably alter the disease course
of relapsing-remitting multiple sclerosis (RRMS) patients. Although its mod
e of action is still unclear, there is ample evidence from in vitro studies
that IFN-beta directly modulates the function of immune cells. We analyzed
here the effects of IFN-beta treatment on immune functions in vivo in a gr
oup of 25 RRMS patients who received IFN-beta (8 MIU) on alternate days. At
baseline and at 1, 3 and 6 months from the start of the treatment, paramet
ers for differentiation and activation states of both monocytes and T lymph
ocytes were assessed. A transient increase was seen in plasma (p) interleuk
in (IL)-10 level whereas pIL-12 (p40) was not affected. A similar change wa
s found in the ability of monocytes to secrete these cytokines in vitro. No
tably, patients who in vitro readily responded to IFN-beta with enhanced IL
-10 production had the highest pIL-10 levels. Concerning T-cell differentia
tion, flowcytometric analysis of cytokine production showed that treatment
with IFN-beta moderately decreased the mean percentages of CD8(pos) T cells
producing IL-2 and IFN-gamma and CD8(neg) T cells producing IL-4 (p < 0.05
for all cytokines), whereas a more significant decline was seen in the mea
n percentage of CD8(neg) T cells producing IFN-gamma (p < 0.01). This resul
ted in a significant lower ratio T-HELPER(H)1 vs. T-HELPER(H)2 type cells i
n the CD8(pos) T-cell subset (p < 0.05); but not in the CD8(neg) T-cell sub
set. Finally, IFN-beta treatment resulted in an initial rise in the mean pe
rcentage of CD95(pos) T cells and in a gradual increase in the mean level o
f soluble CD95 (sCD95) in plasma (p < 0.01). Additional in vitro studies sh
owed that IFN-beta indeed rapidly (within 24 h) upregulates CD95 expression
on both primed and unprimed T cells and augments the release of sCD95 in c
ulture supernatants. Thus, we confirm here that IFN-beta treatment leads to
similar changes in cytokine production of T cells and monocytes as previou
sly described in vitro. Enhanced IL-10 secretion may downmodulate cytokine
secretion by activated T cells and in this way dampen newly-induced and/or
ongoing immune responses. In addition, we identified a novel effect of IFN-
beta treatment, i.e., induction of CD95 expression. The augmentation of CD9
5 expression may directly interfere with T-cell selection, notably of autoa
ggressive T cells. Future studies are needed to show whether this increased
CD95 expression indeed leads to increased apoptosis of immune cells. (C) 1
999 Elsevier Science B.V. All rights reserved.